Sanofi and the American Medical Directors Association Foundation Sponsor Study Using PositiveID Corporation's iglucose Mobile Health System for Diabetes Management

Sanofi Will Support the Study Featuring 200 Patients With Type 2 Diabetes

Delray Beach, Florida, UNITED STATES

DELRAY BEACH, Fla., Oct. 4, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management and clinical diagnostics, announced today that its iglucose™ mobile health system to facilitate diabetes management will be used in a diabetes study sponsored by the American Medical Directors Association ("AMDA") Foundation and supported by Sanofi.

PositiveID's iglucose system uses mobile technology to seamlessly communicate blood glucose readings from data-capable glucometers to the iglucose diabetes management portal where electronic logbooks and trend reports can be created. From the web-based portal, glucose readings can be shared automatically with caregivers and healthcare professionals via text message, email or fax.

The main objective of the study is to demonstrate the superior efficacy of basal/bolus insulin over sliding scale insulin in reducing mean fasting blood glucose concentration averaged over days 21-28 in nursing home patients with type 2 diabetes by use of an algorithmic conversion tool. The facility's nursing staff will use iglucose on a daily basis to assist in collecting and graphing data over a one-week period (blood glucose testing performed four times per day – prior to meals and at bedtime). There will be a consistent blood glucose testing process applied to all patients enrolled in the study.

William J. Caragol, Chief Executive Officer of PositiveID, said, "We are very pleased that the AMDA Foundation has selected iglucose to simplify their data collection processes for this important study to improve diabetes treatment methods."

More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The Centers for Disease Control and Prevention predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. Worldwide, the number of adults with diabetes has doubled over the last three decades to nearly 350 million and increased nearly three-fold in the U.S., according to a study published in the British journal Lancet. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. was estimated at $174 billion in 2007.

For more information on iglucose, please visit This product has not been cleared for sale by the U.S. Food and Drug Administration.

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit

The PositiveID Corporation logo is available at

Statements about PositiveID's future expectations, including the likelihood that iglucose will be used in a diabetes study sponsored by the AMDA Foundation and supported by Sanofi; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize the iglucose system; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Contact Data